I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 20 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NWm5OVJY[3m2b4TvfIlkcXS7IHHzd4F6 MkL2glExOCEQvF2= M332SGROW09? NY\6NXBTUUN3ME2yOkBvVQ>? MVWyNVk3PDN2MB?=
RS4;11 MWPjfZRwfG:6aXPpeJkh[XO|YYm= NFvibnp,OTByIN88US=> NI\FS2pFVVOR NE\EclJKSzVyPUG5NkBvVQ>? NYm4enlWOjF7NkSzOFA>
MOLM13 MX\jfZRwfG:6aXPpeJkh[XO|YYm= M33reZ4yODBizszN NFvadYZFVVOR MkTzTWM2OD1zMkCgcm0> MUmyNVk3PDN2MB?=
NOMO1 NInL[3NkgXSxdH;4bYNqfHliYYPzZZk> MYL+NVAxKM7:TR?= MoXLSG1UVw>? NFfyXWVKSzVyPUG1JI5O MWCyNVk3PDN2MB?=
HEL M2\ieYN6fG:2b4jpZ4l1gSCjc4PhfS=> NEfWSGh,OTByIN88US=> MV\EUXNQ MlXjTWM2OD1zIN88US=> M2DOW|IyQTZ2M{Sw
K562 NIfuWlVkgXSxdH;4bYNqfHliYYPzZZk> M3\xZ54yODBizszN NYfkV2ZCTE2VTx?= MY\JR|UxRjFyMDFOwG0> M{jHN|IyQTZ2M{Sw
MEG01 MmHNZ5l1d3SxeHnjbZR6KGG|c3H5 NFTqNYh,OTByIN88US=> MV;EUXNQ MXnJR|UxRTJ3IN88US=> M2W5UVIyQTZ2M{Sw
HL60 MV7jfZRwfG:6aXPpeJkh[XO|YYm= NHf4[29,OTByIN88US=> MXzEUXNQ M1KyTWlEPTB;OEmwJI5O MkGyNlE6PjR|NEC=
MV4;11 NFvoTpdCeG:ydH;zbZMh[XO|YYm= MVL+NVAxKM7:TR?= MVXEUXNQ M1O0VYlv\HWlZYOgZZBweHSxc3nz NIDqfIMzOTl4NEO0NC=>
MOLM13 NHi2PVlCeG:ydH;zbZMh[XO|YYm= MVP+NVAxKM7:TR?= MmPPSG1UVw>? NFq5fllqdmS3Y3XzJIFxd3C2b4Ppdy=> MV[yNVk3PDN2MB?=
MV4;11 M2fjSmZ2dmO2aX;uJIF{e2G7 M2nJOmROW09? M3jadYRm[3KnYYPld{B1cGVicnXjdpVqfG2nboSgc4YhSlKGMz:0JIFv\CCrbYDhbZJm\CC{ZXPyeYl1dWWwdDDv[kBETEt7IHHu[EBRSUZzIITvJJRp\SC2cnHud4NzcXC2aX;uZYwhe3SjcoSgd4l1\Q>? M2ewVVIyQTZ2M{Sw
PBMC M{iwNWZ2dmO2aX;uJIF{e2G7 NFvtPIpFVVOR MWXpcohq[mm2czDJUE03KHerdHigdGlEPTBib3[gOk44 NGXDVVAzOjR|N{GxOS=>
A2 NXvRdY04TnWwY4Tpc44h[XO|YYm= MmLuglExKM7:TR?= Mo\vSG1UVw>? NHKyZVBz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG= M2X3SlI{OjV3MkG4
A72 MUfGeY5kfGmxbjDhd5NigQ>? M1Hsbp4yOCEQvF2= MWDEUXNQ M1TxU5Jm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= MmrHNlMzPTV{MUi=
BC1 MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmHpglEh|ryP Mn3nSG1UVw>? NVvZbIt7UUN3ME2yNlAhdk1? M3rWb|I{Pzl{NES4
BC3 MnXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUX+NUDPxE1? NHSyWpVFVVOR MmnlTWM2OD12NkCgcm0> NHK4dIIzOzd7MkS0PC=>
BCBL1 MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUD5Zoc1hjFizszN NEi4VW9FVVOR Mm\ZTWM2OD1|M{Cgcm0> MnXONlM4QTJ2NEi=
BJAB MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn7QglEh|ryP MluxSG1UVw>? NH\PXYRKSzVyPUm3NEBvVQ>? MknpNlM4QTJ2NEi=
Namalwa M4\0VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEHIdpp,OSEQvF2= NV3RVXBRTE2VTx?= MoO4TWM2OD17N{Cgcm0> M1K5dFI{Pzl{NES4
Jurkat Mnn3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3i1RZ4yKM7:TR?= NV;IV5lOTE2VTx?= NF\TbmxKSzVyPUGyNlAhdk1? NFfoXFEzOzd7MkS0PC=>
MM1S MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYDSR|ZthjFizszN NEHFSmRFVVOR M13TNWlEPTB;N{[wJI5O MYeyN|c6OjR2OB?=
U266 Mnj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NG\heph,OSEQvF2= M2HSXmROW09? M{jkNmlEPTB;OUWwJI5O MY[yN|c6OjR2OB?=
UM-PEL-1 MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIjOR2l,OSEQvF2= MoDiSG1UVw>? MWjJR|UxRTJzMDDuUS=> MVyyN|c6OjR2OB?=
UM-PEL-3 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Ml7MglEh|ryP NYLXbHhVTE2VTx?= NV3yUIUxUUN3ME2xPFAhdk1? M3rRelI{Pzl{NES4
BC1 MoDSSpVv[3Srb36gZZN{[Xl? M1nqbFUxOCCwTR?= NGLySYVFVVOR M{jvNolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= MUKyN|c6OjR2OB?=
BC3 M3z1RmZ2dmO2aX;uJIF{e2G7 MVe1NFAhdk1? MlXCSG1UVw>? MWfpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 MkfnNlM4QTJ2NEi=
BC1 NWPDemJwTnWwY4Tpc44h[XO|YYm= NEK4W4c5ODBibl2= MYnEUXNQ M3PQ[5Jm\HWlZYOgZ{1OgWNicILveIVqdiCuZY\lcJM> Mm\HNlM4QTJ2NEi=
BC3 MX3GeY5kfGmxbjDhd5NigQ>? MWW4NFAhdk1? NF3yRXZFVVOR NGm0NJFz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ MVSyN|c6OjR2OB?=
H929 M{O3PGZ2dmO2aX;uJIF{e2G7 NHPQ[nZ,OSEQvF2= MXjEUXNQ MXrpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MYGyOFM{PTR7OR?=
KMS12PE MUnGeY5kfGmxbjDhd5NigQ>? MYf+NUDPxE1? NWrsS2VuTE2VTx?= NGjHXWlqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NWDsfHJDOjR|M{W0PVk>
KMS12BM MknNSpVv[3Srb36gZZN{[Xl? MUT+NUDPxE1? MW\EUXNQ NV7iWHN[cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NVXwNWFHOjR|M{W0PVk>
KMS18 NEnrRmNHfW6ldHnvckBie3OjeR?= M4j2cZ4yKM7:TR?= MYXEUXNQ MV3pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NW\iPGJjOjR|M{W0PVk>
KMS11 NXnuUnl[TnWwY4Tpc44h[XO|YYm= M4\IOJ4yKM7:TR?= MWHEUXNQ M3j2RYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= Ml3nNlQ{OzV2OUm=
RPMI8226 M2HxPWZ2dmO2aX;uJIF{e2G7 NWfhOXhQhjFizszN MVXEUXNQ M2S0V4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MnTyNlQ{OzV2OUm=
H929 NGXMVHVCeG:ydH;zbZMh[XO|YYm= NW\r[nJkhjFizszN MUPEUXNQ NV\5cZRvcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEThToYzPDN|NUS5PS=>
KMS12PE NFzRPW9CeG:ydH;zbZMh[XO|YYm= M{DTO54yKM7:TR?= NXzyUnBqTE2VTx?= NXviV2ZJcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXyyOFM{PTR7OR?=
KMS12BM M3LEZmFxd3C2b4Ppd{Bie3OjeR?= NVS4eG16hjFizszN M4rmd2ROW09? M1O2U4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmHhNlQ{OzV2OUm=
KMS18 NYPKd3ZVSXCxcITvd4l{KGG|c3H5 M3nQb54yKM7:TR?= MUHEUXNQ NF7GSmVqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmnINlQ{OzV2OUm=
KMS11 NF7hNFVCeG:ydH;zbZMh[XO|YYm= M{nPV54yKM7:TR?= M4nJd2ROW09? NV7VXW5ZcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MVOyOFM{PTR7OR?=
RPMI8226 MWXBdI9xfG:|aYOgZZN{[Xl? NEXlTml,OSEQvF2= MlnKSG1UVw>? MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXmyOFM{PTR7OR?=
U87MG NFS4dmtHfW6ldHnvckBie3OjeR?= M4fveJ4yOCEQvF2= NHzOfnVFVVOR NEHMNY9z\WS3Y3XzJHU5P02JIHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6wOUDPxE1? NHO2PXkzPDR7NkO4NS=>
A172 MmHZSpVv[3Srb36gZZN{[Xl? NXzWWY5xhjFyIN88US=> M2qy[2ROW09? MYPy[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6yPEDPxE1? MXiyOFQ6PjN6MR?=
SW1783 NHmwOnFHfW6ldHnvckBie3OjeR?= M2rBOJ4yOCEQvF2= NIjpOI9FVVOR NGLyTodz\WS3Y3XzJINmdGy3bHHyJGFVWCC5aYToJGlEPTBib3[gNk43QCEQvF2= NHPHcI4zPDR7NkO4NS=>
U87MG NXXYfHNHTnWwY4Tpc44h[XO|YYm= MlT1glExKM7:TR?= M13iO2ROW09? MUHpcoNz\WG|ZYOgdJJweG:{dHnvckBw\iClZXzsd{BqdiC2aHWgS|EwWyC2cnHud4l1cW:w NF70fZgzPDR7NkO4NS=>
RAW267.4 MULGeY5kfGmxbjDhd5NigQ>? MnrnNUDPxE1? NIe1NlBFVVOR M4DHSpJm\HWlZYOgTWwuPiCycn;keYN1cW:wIHnu[JVk\WRiYomgUHBU MUKyOFg2QTByOB?=
RAW267.4 M2j5SGZ2dmO2aX;uJIF{e2G7 NIrvcHQyKM7:TR?= NGfKfYtFVVOR NYfGR5FwemWmdXPld{B1cGViYYPzc4Nq[XSrb36gZoV1f2WnbjDCVmQ1KGGwZDDhZ4V1gWyjdHXkJJA3PQ>? M3HlNFI1QDV7MEC4
Me007 MmD4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYj+NVAxKM7:TR?= NFnHNZlFVVOR MXPpcohq[mm2czD0bIUh\3Kxd4To NFnBTowzPDlyNkGzOy=>
SK-Mel-28 MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NET6WZV,OTByIN88US=> MV3EUXNQ NHu2RWJqdmirYnn0d{B1cGViZ4Lve5Rp MXmyOFkxPjF|Nx?=
Mel-RMU M1jUWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWj+NVAxKM7:TR?= MVHEUXNQ MkfPbY5pcWKrdIOgeIhmKGe{b4f0bC=> MUiyOFkxPjF|Nx?=
Mel-JD MmfjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2e3Z54yODBizszN NXfhTlh5TE2VTx?= MVvpcohq[mm2czD0bIUh\3Kxd4To MnHNNlQ6ODZzM{e=
Mel-RM NFPYbXRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHTQV3R,OTByIN88US=> NFGzTJBFVVOR MmrZbY5pcWKrdIOgeIhmKGe{b4f0bC=> M4\1S|I1QTB4MUO3
Me007 M17JVWFxd3C2b4Ppd{Bie3OjeR?= MYf+NVAxKM7:TR?= M3yyb2ROW09? MYrpcoR2[2W|IHHwc5B1d3Orcx?= M1rDS|I1QTB4MUO3
SK-Mel-28 NHTkfnlCeG:ydH;zbZMh[XO|YYm= M3vCXZ4yODBizszN Mkn3SG1UVw>? Mne3bY5lfWOnczDhdI9xfG:|aYO= MWGyOFkxPjF|Nx?=
Mel-RMU MX;BdI9xfG:|aYOgZZN{[Xl? M13reZ4yODBizszN NWLsbHZ2TE2VTx?= NH7DRoZqdmS3Y3XzJIFxd3C2b4Ppdy=> MXKyOFkxPjF|Nx?=
Mel-JD M{GzWGFxd3C2b4Ppd{Bie3OjeR?= NIC1Opl,OTByIN88US=> MlHISG1UVw>? NFzmNoFqdmS3Y3XzJIFxd3C2b4Ppdy=> MVWyOFkxPjF|Nx?=
Mel-RM MU\BdI9xfG:|aYOgZZN{[Xl? NI\5U2d,OTByIN88US=> NX72UGZTTE2VTx?= M1jwbolv\HWlZYOgZZBweHSxc3nz NE\iTmUzPDlyNkGzOy=>
Me007 NEXzWHdHfW6ldHnvckBie3OjeR?= Mn[2NVAh|ryP MXnEUXNQ NH\l[29qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? MlTtNlQ6ODZzM{e=
SK-Mel-28 M1zmV2Z2dmO2aX;uJIF{e2G7 NEHCPJMyOCEQvF2= Mm\pSG1UVw>? MXrpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MYCyOFkxPjF|Nx?=
Mel-RMU NVKwS3pbTnWwY4Tpc44h[XO|YYm= M1u3V|ExKM7:TR?= NVzKWZhVTE2VTx?= M4S2Nolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NED1NpMzPDlyNkGzOy=>
Mel-JD MYLGeY5kfGmxbjDhd5NigQ>? NYfxZnA1OTBizszN M2DQeWROW09? NH:0eJhqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? MX[yOFkxPjF|Nx?=
Mel-RM MojYSpVv[3Srb36gZZN{[Xl? NGHkenYyOCEQvF2= MXTEUXNQ MUTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NUTOXlNyOjR7ME[xN|c>
Me007 MojRSpVv[3Srb36gZZN{[Xl? NU\EXodGOTBizszN MXjEUXNQ NVjrbodofXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> NIP0T4YzPDlyNkGzOy=>
SK-Mel-28 NGHERXlHfW6ldHnvckBie3OjeR?= NWfjcXNROTBizszN NWXZTIR2TE2VTx?= NIPYPIx2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NF:0PJAzPDlyNkGzOy=>
Mel-RMU MUPGeY5kfGmxbjDhd5NigQ>? NVfEfWFYOTBizszN NH;aTWxFVVOR M4Tvd5VxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NFXLWYYzPDlyNkGzOy=>
Mel-JD M4fJ[mZ2dmO2aX;uJIF{e2G7 M2HlcFExKM7:TR?= NYnzO|lwTE2VTx?= MkPTeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= M4mwO|I1QTB4MUO3
Mel-RM NF;2TnNHfW6ldHnvckBie3OjeR?= NUDnd4ZWOTBizszN NGjYSZFFVVOR MmDYeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NVvy[HJ2OjR7ME[xN|c>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / Fibronectin / Collagen-1; 

PubMed: 27732564     


Normally cultured NRK-49F cells were treated with I-BET151 (0-5μM) for 36 h. Then, cell lysates were prepared and subjected to immunoblot analysis with antibodies against α-SMA, collagen-1, fibronectin, and GAPDH.

FoxM1 / AURKB / Survivin / cyclin B / PLK1; 

PubMed: 26877780     


OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies. 

HP1α / HP1β / HP1γ; 

PubMed: 30386240     


Protein expression levels of HP1α, β, and γ in U937, R-U937, HL-60, and R-HL-60 cells after incubation with I-BET151 at indicated dose for 48 h. Typical blots from a representative experiment are shown. The experiments were repeated three times.

27732564 26877780 30386240
In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

- Collapse

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

- Collapse
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID